Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

FERTIN PHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 7.1% 7.1%   Bankruptcy risk   0.4% 2.3% 2.2% 2.2% 3.6% 3.0% 3.0% 3.0%   Credit score (0-100)   99 66 65 64 52 57 58 58   Credit rating   AAA BBB BBB BBB BBB BBB BBB BBB   Credit limit (mDKK)   99.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   813 882 991 933 893 1,013 1,013 1,013   Gross profit   121 882 991 933 25.2 34.1 0.0 0.0   EBITDA   185 138 192 96.0 54.2 45.0 0.0 0.0   EBIT   90.4 138 192 96.0 -74.8 -75.9 0.0 0.0   Pre-tax profit (PTP)   61.6 81.0 155.0 38.0 -113.6 -163.0 0.0 0.0   Net earnings   45.8 81.0 155.0 38.0 -91.4 -136.7 0.0 0.0   Pre-tax profit without non-rec. items   61.6 138 192 96.0 -114 -163 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   1,179 0.0 0.0 0.0 1,176 1,193 0.0 0.0   Shareholders equity total   896 778 770 681 596 458 61.4 61.4   Interest-bearing liabilities   843 0.0 0.0 0.0 1,238 1,601 12.5 12.5   Balance sheet total (assets)   2,004 1,894 1,998 2,021 2,249 2,498 73.9 73.9   Net Debt   759 0.0 0.0 0.0 1,211 1,596 12.5 12.5     See the entire balance sheet 1.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   813 882 991 933 893 1,013 1,013 1,013   Net sales growth   -6.4% 8.6% 12.4% -5.9% -4.3% 13.4% 0.0% 0.0%   Gross profit   121 882 991 933 25.2 34.1 0.0 0.0   Gross profit growth   -41.8% 626.8% 12.4% -5.9% -97.3% 35.7% -100.0% 0.0%   Employees   674 569 622 654 690 798 0 0   Employee growth %   2.0% -15.6% 9.3% 5.1% 5.5% 15.7% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,004 1,894 1,998 2,021 2,249 2,498 74 74   Balance sheet change%   23.1% -5.5% 5.5% 1.2% 11.3% 11.1% -97.0% 0.0%   Added value   184.7 138.0 192.0 96.0 -74.8 45.0 0.0 0.0   Added value %   22.7% 15.6% 19.4% 10.3% -8.4% 4.4% 0.0% 0.0%   Investments   77 -1,435 0 0 1,469 -45 -1,601 0   Net sales trend   -1.0 1.0 2.0 -1.0 -2.0 1.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 -1.0 -2.0 0.0 0.0   1.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   22.7% 15.6% 19.4% 10.3% 6.1% 4.4% 0.0% 0.0%   EBIT %   11.1% 15.6% 19.4% 10.3% -8.4% -7.5% 0.0% 0.0%   EBIT to gross profit (%)   74.5% 15.6% 19.4% 10.3% -297.3% -222.3% 0.0% 0.0%   Net Earnings %   5.6% 9.2% 15.6% 4.1% -10.2% -13.5% 0.0% 0.0%   Profit before depreciation and extraordinary items %   17.2% 9.2% 15.6% 4.1% 4.2% -1.6% 0.0% 0.0%   Pre tax profit less extraordinaries %   7.6% 15.6% 19.4% 10.3% -12.7% -16.1% 0.0% 0.0%   ROA %   4.4% 7.1% 9.9% 4.8% -4.7% -4.6% 0.0% 0.0%   ROI %   4.9% 7.4% 9.9% 4.8% -5.0% -5.2% 0.0% 0.0%   ROE %   5.5% 9.7% 20.0% 5.2% -14.3% -25.9% 0.0% 0.0%   1.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   44.7% 100.0% 100.0% 100.0% 26.5% 18.3% 83.1% 83.1%   Relative indebtedness %   124.1% 0.0% 0.0% 0.0% 169.5% 189.0% 1.2% 1.2%   Relative net indebtedness %   113.7% 0.0% 0.0% 0.0% 166.6% 188.5% 1.2% 1.2%   Net int. bear. debt to EBITDA, %   411.0% 0.0% 0.0% 0.0% 2,234.7% 3,542.9% 0.0% 0.0%   Gearing %   94.1% 0.0% 0.0% 0.0% 207.5% 349.4% 20.3% 20.3%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.6% 0.0% 0.0% 0.0% 2.3% 3.8% 0.0% 0.0%   1.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.8 0.0 0.0 0.0 0.2 1.5 0.0 0.0   Current Ratio   1.3 0.0 0.0 0.0 0.4 2.4 0.0 0.0   Cash and cash equivalent   84.6 0.0 0.0 0.0 26.4 5.8 0.0 0.0   1.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   67.0 0.0 0.0 0.0 64.1 53.9 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   68.3% 0.0% 0.0% 0.0% 65.6% 74.7% 0.0% 0.0%   Net working capital   127.5 0.0 0.0 0.0 -890.8 444.3 -6.2 -6.2   Net working capital %   15.7% 0.0% 0.0% 0.0% -99.8% 43.9% -0.6% -0.6%   1.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   1 2 2 1 1 1 0 0   Added value / employee   0 0 0 0 -0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 -0 -0 0 0   Net earnings / employee   0 0 0 0 -0 -0 0 0